Latest News

New hematologic, cardiovascular system link may have therapeutic implications


 

EXPERT ANALYSIS FROM ASH 2017

“If we understand that, we may be in a position to stratify these women based on thrombosis risk in the setting of estrogen exposure. I think the other thing that will come out of the work, as we begin to understand the mechanisms for this relationship, is the identification of targets that we could therapeutically modulate to reduce this risk,” he added.

Eventually, as more is learned about the mechanisms that underlie the relationship between OPA1 and platelet activation, the findings might also lead to new approaches for reducing the risk of thrombosis in men, he noted.

Dr. Abel and Dr. Weyrich reported having no relevant financial disclosures.

Pages

Recommended Reading

VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
MDedge Hematology and Oncology
Thrombosis risk is elevated with myeloproliferative neoplasms
MDedge Hematology and Oncology
Surgical LAA occlusion tops anticoagulation for AF thromboprotection
MDedge Hematology and Oncology
Low inhibitor rate observed in PUPs with hemophilia A
MDedge Hematology and Oncology
FDA approves ready-to-use bivalirudin
MDedge Hematology and Oncology
FDA surveillance shows how rivaroxaban compares to warfarin
MDedge Hematology and Oncology
EC approves product to treat hemophilia A
MDedge Hematology and Oncology
Emicizumab still available despite legal issues
MDedge Hematology and Oncology
Update of gene therapy in hemophilia A
MDedge Hematology and Oncology
Caplacizumab improves outcomes in aTTP
MDedge Hematology and Oncology

Related Articles